

Barcelona, March 4th 2019

SIGNIFICANT EVENT

Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business

Almirall, S.A. (ALM.MC), as per section 228 of the Royal Legislative Decree 4/2015, of 23 October 2015, approving the Restated Text of the Securities Market Act, hereby announces that:

Almirall entered into a definitive agreement with Celling Biosciences to divest ThermiGen for an undisclosed amount. The transaction is expected to close before or on March 29th, 2019.

In 2018, ThermiGen generated 16 MME of Net Sales and had 94 employees, based in Dallas (Texas). It has an installed base of more than 2,000 users with a strong presence across the U.S.

The transaction announced today does not affect Almirall Guidance for 2019 year, which was published on February 25th, 2019.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations & Corporate Comms. Department
investors@almirall.com